Guangdong Jianersheng Pharmaceutical Technology

Guangdong Jianersheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the research and development of innovative small molecule drugs. The company primarily focuses on the fields of immunology and oncology, utilizing its expertise in medicinal chemistry to develop highly selective kinase inhibitors. Its lead candidate, JX-001, is a potent and selective TYK2 inhibitor currently undergoing clinical evaluation for the treatment of autoimmune diseases such as psoriasis. Beyond its lead program, the company is advancing a pipeline of candidates targeting JAK1 and other key signaling pathways involved in inflammatory and malignant processes. Jianersheng aims to provide more effective and safer therapeutic options for patients worldwide through rigorous scientific innovation.